SPEECH-PROCESSING-SOLUTI
27.9.2016 09:06:23 CEST | Business Wire | Press release
Speech Processing Solutions , the world number 1 for professional dictation solutions , is proud to announce very positive feedback on its latest voice recorder, the Philips SpeechAir, and the SpeechLive cloud solution, which now also offers speech recognition.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160927005172/en/
Both SpeechAir and SpeechLive are ideally suited to professionals who are often on the move and do not always work from their usual office workplace. Ingo Bischof, MBA, Managing Director of IVAM Real Estate, is delighted with the advantages of these two solutions: "With Philips dictation solutions it is possible for us to log and record issues in the properties that we maintain significantly more quickly. The recordings are then sent to our back office, saving us a considerable amount of time, as transcription can begin before we return to the office."
Exceptional recording quality and intuitive slide switch recording control
The SpeechAir is equipped with three professional-quality microphones providing ultimate sound quality in any recording situation . Background noise is filtered and the voices are recorded in perfect quality. This ensures excellent playback and speech recognition results. At the start of the year, the SpeechAir was awarded Nuance Communications' rating for best recording accuracy . The slide switch provides an efficient and intuitive user interface operated with just one hand. Recordings can be started, paused, stopped, played back, rewound and fast-forwarded using the slide switch .
Stay connected with the Wi-Fi and Bluetooth functions
The Wi-Fi and Bluetooth connections allow wireless transfer of finished recordings and access to the customer's data in the respective document management system, email or calendar. Dr Doris Ulreich-Laussermayer, a doctor in obstetrics and gynaecology, appreciates this function. "I can send additions to the PC in the medical practice via Wi-Fi on the move or from home and my assistant can edit them. Another thing that I especially like about SpeechAir is its portability, as I can move freely around the practice. The SpeechAir's antimicrobial surface is another positive aspect for hygiene in my medical practice," says the doctor.
SpeechLive speech recognition – speak, send, receive the finished document
The Philips SpeechLive cloud dictation solution now includes speech recognition available in 21 languages. Spoken words are converted into a written text in next to no time. SpeechLive can be used at any time and is easily accessible via any web browser with no software installation required. "Our company is split between two different locations. Last week I was working in the office in Melbourne; this week I am outside of the city in Mount Waverley. It's great to be able to work from anywhere, without having to think about taking something with me. I can sign in from any computer," raves Nicole Honan, Office Manager at the law firm Hicks Oakley Chessell Williams in Australia.
For more information about our solutions visit:
About Speech Processing Solutions
Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir , the Philips Pocket Memo voice recorder , the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the newest innovation, Philips SpeechLive , dictations and recordings will become faster and easier than ever before with cloud-based workflow services. Speech Processing Solution's perfectly tailored offers and products help professionals save time and resources and maximize efficiency.
Connect with Speech Processing Solutions on:
Facebook: http://www.facebook.com/philipsvoicetracer
Instagram: https://www.instagram.com/philips_dictation/
Twitter @speech_com: http://www.twitter.com/speech_com
YouTube: http://www.youtube.com/philipsdictation
LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
View source version on businesswire.com: http://www.businesswire.com/news/home/20160927005172/en/
Contact:
Speech Processing Solutions
Christina Angerer
christina.angerer@speech.com
Tel:
+43 1605 291 488
www.philips.com/dictation
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom